SCHEMBL3083131

SCHEMBL3083131

NC(=O)c1ccc(-c2ccncc2)cc1C1=CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHUK O15111 5/20 0.52
CDC7 O00311 3/20 0.51
CDK9 P50750 1/20 0.51
CSF1R P07333 3/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
IKBKB O14920 5/20 0.44
KDR P35968 2/20 0.44
IKBKE Q14164 2/20 0.43
PKMYT1 Q99640 1/20 0.43
MKNK2 Q9HBH9 4/20 0.43
ROCK2 O75116 2/20 0.43
MAP4K4 O95819 2/20 0.43
GSK3B P49841 2/20 0.43
CLK4 Q9HAZ1 2/20 0.43
ACMSD Q8TDX5 1/20 0.42
MKNK1 Q9BUB5 3/20 0.40
GRM2 Q14416 1/20 0.40
CHEK2 O96017 1/20 0.40
PIM1 P11309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3083329 0.85 MKNK1 (0.58) CSF1RMKNK2MKNK1CHEK2
SCHEMBL3086556 0.81 CSF1R (0.55) CSF1RCYP3A4CYP2C9MKNK2MAP4K4
SCHEMBL3089990 0.81 CSF1R (0.53) CSF1RACMSDGRM2CHEK2
SCHEMBL3083133 0.80 KDR (0.48) CSF1RCYP3A4CYP2C9KDR
SCHEMBL3917188 0.79 ACMSD (0.40) CSF1RCYP3A4CYP2C9MAP4K4ACMSD
SCHEMBL3076858 0.78 CSF1R (0.48) CSF1RACMSDGRM2
SCHEMBL3081416 0.77 ACMSD (0.38) CSF1RCYP3A4CYP2C9IKBKEACMSD
SCHEMBL3076846 0.77 PSMB5 (0.46) CSF1RIKBKBACMSDGRM2
SCHEMBL3915817 0.76 ACMSD (0.37) CSF1RCYP3A4CYP2C9IKBKEACMSD
SCHEMBL3910409 0.75 ACMSD (0.41) CSF1RIKBKBACMSDGRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US claimed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP claimed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO claimed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US claimed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER CHUK 39/4885CDC7 294/4885CDK9 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.